Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Leaps by Bayer

Investor type Corporate Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 53
Average round size
info
The average size of a deal this fund participated in
$61M
Portfolio companies 44
Rounds per year 7.57
Lead investments 10
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Agriculture
Summary

Leaps by Bayer appeared to be the Corporate Investor, which was created in 2015. The main department of described Corporate Investor is located in the Leverkusen. The company was established in Europe in Germany.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Leaps by Bayer, startups are often financed by Longwood Founders Fund, Ipsen, Agent Capital. The meaningful sponsors for the fund in investment in the same round are Longwood Founders Fund, Ipsen, Agent Capital. In the next rounds fund is usually obtained by Longwood Founders Fund, Ipsen, Agent Capital.

Besides, a startup needs to be aged 1 and less years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Century Therapeutics, Pyxis Oncology, Pyxis Oncology Among the most popular fund investment industries, there are Therapeutics, Pharmaceutical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups.

The high activity for fund was in 2019. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. Speaking about the real fund results, this Corporate Investor is 47 percentage points more often commits exit comparing to other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Leaps by Bayer:
Typical Co-investors
Leaps by Bayer is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Leaps by Bayer:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
BAIC Capital Beijing, Beijing, China
Bond California, San Francisco, United States
BrainTrust Lisboa, Lisbon, Portugal
Enchant Central, Central Region, Singapore
GBIC New York, New York, United States
Grafton Group County Dublin, Dublin, Ireland
ICBC International China, Hong Kong, Hong Kong Island
Jimin Kexin Pharmaceutical -
Kamatech Accelerator -
Luzerner Kantonalbank Lucerne, Luzern, Switzerland
Manufacturing Resources International Georgia, Louisiana, United States
Nameless Ventures Chicago, Illinois, United States
Ningbo Huatong Chuangtou China, Ningbo, Zhejiang
Nirvana Capital Beijing, Beijing, China
Shanghai Qiyin China, Shanghai
Sino Agri China, Guangdong, Shenzhen
Sorenson Capital Lehi, United States, Utah
UCLA Ventures California, Los Angeles, United States
Zhongjian Touzi China, Minhang, Shanghai
Zhongliang Qihuo Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

NuCicer

Bioinformatics
Genetics
$2M03 Nov 2022 Davis, California, United States

Capstan Therapeutics

Biotechnology
Health Care
Therapeutics
$102M14 Sep 2022 San Diego, California, United States

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$120M29 Jun 2022 Dallas, Texas, United States

Senti Biosciences

Biotechnology
Health Care
Medical
Therapeutics
$50M09 Jun 2022 South San Francisco, California, United States

Senti Biosciences

Biotechnology
Health Care
Medical
Therapeutics
$5M24 May 2022 South San Francisco, California, United States

9am.health

Health Care
Medical
Wellness
$16M13 Apr 2022 Encinitas, California, United States

Affini-T Therapeutics

Biotechnology
Health Care
Therapeutics
$175M22 Mar 2022 Watertown, Massachusetts, United States

Apollo Agriculture

Agriculture
Farmers Market
Financial Services
Machine Learning
$40M21 Mar 2022 Nairobi, Nairobi, Kenya

Triumvira Immunologics

Biotechnology
Clinical Trials
Health Care
$45M17 Mar 2022 Austin, Texas, United States
News
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

Zerigo Health Raises $43 Million in Series B Funding to Drive Adoption of the Industry’s Only Connected Light Therapy Solution to Treat Chronic Skin Conditions

– Zerigo Health announced a $43m Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer.
– The round also included participation by existing investors including SV Health Investors, H.I.G. Capital, and Bluestem Capital.
– This round will allow Zerigo Health to respond to the increasing demand for its innovative connected chronic skin condition solution for the over 40 million Americans living with psoriasis, vitiligo, and eczema.
– Glen Tullman, Managing Partner of 7wireVentures, former Founder and CEO of Livongo, and Chief Executive Officer of Transcarent, will join as Executive Chairman of the company’s Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Leaps by Bayer?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: